|
1
|
SOCS2 negatively regulates growth hormone action in vitro and in vivo.
|
J Clin Invest
|
2005
|
1.66
|
|
2
|
Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1.
|
Biochem J
|
2013
|
1.45
|
|
3
|
SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities.
|
Biochemistry
|
2002
|
1.27
|
|
4
|
Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling.
|
J Biol Chem
|
2002
|
1.26
|
|
5
|
Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides.
|
J Med Chem
|
2008
|
1.17
|
|
6
|
Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain.
|
FEBS J
|
2005
|
1.14
|
|
7
|
Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production.
|
Am J Respir Cell Mol Biol
|
2008
|
0.91
|
|
8
|
One-step zero-background IgG reformatting of phage-displayed antibody fragments enabling rapid and high-throughput lead identification.
|
Nucleic Acids Res
|
2013
|
0.80
|
|
9
|
EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE).
|
PLoS One
|
2013
|
0.79
|
|
10
|
Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment.
|
J Mol Biol
|
2008
|
0.78
|